BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36402055)

  • 21. Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario.
    Lee GY; Inthasorn P; Laowahutanont P; Lawpoolsri S; Kamolratanakul S; Lungchukiet P; Oh J; Termrungruanglert W; Taechakraichana N; Pitisuttithum P
    Vaccine; 2022 Mar; 40(13):1968-1976. PubMed ID: 35190207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
    Combita AL; Reyes V; Puerto D; Murillo R; Sánchez R; Nuñez M; Hernandez-Suarez GA; Wiesner C
    Cancer Prev Res (Phila); 2022 Jan; 15(1):55-66. PubMed ID: 34610993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study.
    Velentzis LS; Sitas F; O'Connell DL; Darlington-Brown J; Egger S; Sinha R; Banks E; Frazer IH; Canfell K
    BMC Infect Dis; 2014 Dec; 14():3861. PubMed ID: 25528152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women.
    Onuki M; Yamamoto K; Yahata H; Kanao H; Yokota H; Kato H; Shimamoto K; Takehara K; Kamiura S; Tsuda N; Takei Y; Shigeta S; Matsumura N; Yoshida H; Motohara T; Watari H; Nakamura K; Ueda A; Tasaka N; Ishikawa M; Hirashima Y; Kudaka W; Taguchi A; Iwata T; Takahashi F; Kukimoto I; Yoshikawa H; Yaegashi N; Matsumoto K;
    Cancer Sci; 2022 Apr; 113(4):1428-1434. PubMed ID: 35043515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials.
    Whitworth HS; Gallagher KE; Howard N; Mounier-Jack S; Mbwanji G; Kreimer AR; Basu P; Kelly H; Drolet M; Brisson M; Watson-Jones D
    Vaccine; 2020 Feb; 38(6):1302-1314. PubMed ID: 31870572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.
    Sigurdsson K; Sigvaldason H; Gudmundsdottir T; Sigurdsson R; Briem H
    Acta Obstet Gynecol Scand; 2009; 88(1):27-35. PubMed ID: 19031282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine.
    Bhatla N; Muwonge R; Malvi SG; Joshi S; Poli URR; Lucas E; Esmy PO; Verma Y; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Vashist S; Mishra G; Jadhav R; Siddiqi M; Anantharaman D; Panicker G; Butt J; Sankaran S; Kannan TPRA; Varghese R; Kartha P; Pillai MR; Waterboer T; Müller M; Sehr P; Unger ER; Sankaranarayanan R; Basu P
    Hum Vaccin Immunother; 2023 Dec; 19(3):2289242. PubMed ID: 38078840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination.
    Cornall AM; Saville M; Pyman J; Callegari ET; Tan FH; Brotherton JML; Malloy MJ; Tabrizi SN; Wrede CD; Garland SM;
    Vaccine; 2020 Sep; 38(40):6304-6311. PubMed ID: 32736938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
    BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
    Joura EA; Leodolter S; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Garland SM; Harper DM; Tang GW; Ferris DG; Steben M; Jones RW; Bryan J; Taddeo FJ; Bautista OM; Esser MT; Sings HL; Nelson M; Boslego JW; Sattler C; Barr E; Paavonen J
    Lancet; 2007 May; 369(9574):1693-702. PubMed ID: 17512854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
    McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
    Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
    Sankaranarayanan R; Prabhu PR; Pawlita M; Gheit T; Bhatla N; Muwonge R; Nene BM; Esmy PO; Joshi S; Poli UR; Jivarajani P; Verma Y; Zomawia E; Siddiqi M; Shastri SS; Jayant K; Malvi SG; Lucas E; Michel A; Butt J; Vijayamma JM; Sankaran S; Kannan TP; Varghese R; Divate U; Thomas S; Joshi G; Willhauck-Fleckenstein M; Waterboer T; Müller M; Sehr P; Hingmire S; Kriplani A; Mishra G; Pimple S; Jadhav R; Sauvaget C; Tommasino M; Pillai MR;
    Lancet Oncol; 2016 Jan; 17(1):67-77. PubMed ID: 26652797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.
    Kreimer AR; Sampson JN; Porras C; Schiller JT; Kemp T; Herrero R; Wagner S; Boland J; Schussler J; Lowy DR; Chanock S; Roberson D; Sierra MS; Tsang SH; Schiffman M; Rodriguez AC; Cortes B; Gail MH; Hildesheim A; Gonzalez P; Pinto LA;
    J Natl Cancer Inst; 2020 Oct; 112(10):1038-1046. PubMed ID: 32091594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
    LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
    Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
    Carozzi F; De Marco L; Gillio-Tos A; Del Mistro A; Girlando S; Baboci L; Trevisan M; Burroni E; Grasso S; Giorgi Rossi P; Ronco G;
    J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial.
    Zhao S; Hu S; Xu X; Zhang X; Pan Q; Chen F; Zhao F
    BMC Infect Dis; 2020 Nov; 20(1):846. PubMed ID: 33198657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology.
    Hampson IN
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.